Omeprazol Basics (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Basics, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Omeprazol Basics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders. - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition. - Helicobacter pylori eradication regimens (as part of combination therapy): enhances eradication rates by maintaining a higher gastric pH. - NSAID‑associated ulcer prophylaxis: lowers the risk of ulcer formation in patients requiring chronic NSAID therapy.

Adverse reactions to omeprazole are generally mild, but they can range from common to serious.

Common Side Effects: - Headache: mild, transient headache reported by some patients. - Diarrhoea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): difficulty breathing, swelling of face or throat. - Clostridioides difficile infection: persistent watery diarrhoea, fever. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: signs of hepatic stress in blood tests. - Stevens‑Johnson syndrome: rare skin blistering and mucosal involvement.

When using Omeprazol Basics, consider the following safety measures: - Assess renal function: adjust use in patients with severe kidney impairment. - Review hepatic status: use with caution in moderate to severe liver disease. - Monitor long‑term therapy: evaluate need for continued treatment after 12 months. - Avoid abrupt discontinuation: taper if therapy has been prolonged to reduce rebound acid hypersecretion. - Pregnancy and lactation: limit use to situations where benefits outweigh risks. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular event risk. - Atazanavir: decreased absorption, compromising HIV therapy effectiveness. - Warfarin: enhanced anticoagulant effect, raising bleeding risk.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum concentrations, may require dose adjustment. - Methotrexate: reduced renal clearance, potential toxicity at high doses. - Phenytoin: altered metabolism, may affect seizure control. - Ketoconazole: decreased absorption, reducing antifungal efficacy.